ACTU — Actuate Therapeutics, Inc.

Is ACTU overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Actuate Therapeutics, Inc. (ACTU) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.27. The rating moved from Oversold to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Actuate Therapeutics, Inc. (ACTU) is a micro-cap biotech/security with limited public disclosure and no clear, visible near-term catalysts. Financial runway and recent filing activity are unclear, increasing the probability of dilutive financing or binary negative moves tied to clinical/regulatory events. The broader market tone currently favors large-cap pharma and defensive healthcare, which reduces speculative appetite for names of this size without strong newsflow. Absent a confirmed financing plan, a material clinical readout, or strategic partnership, downside risk and volatility are likely to remain elevated; a positive outcome (data, partnership, or clear non-dilutive financing) would be the primary path to meaningful upside.

Key factors

  • Very low absolute share price and likely thin liquidity increasing volatility and execution risk for investors.
  • No recent EDGAR comparison data available and limited public information increases uncertainty around financial runway and near-term cash needs.
  • Sector environment favors large-cap pharma and defensive healthcare flows rather than micro/biotech speculative names, limiting positive sentiment tailwinds.
  • Primary value drivers for small biotechs are clinical readouts, partnerships, or clear financing plans; absence of visible near-term catalysts raises downside vulnerability.
  • Convertible-debt and broader biotech financing pressures increase the probability of dilutive financings if cash is needed.

Risks

  • Severe dilution risk from equity raises or convertible financing if the company requires cash to fund operations or trials.
  • Clinical or regulatory setbacks (if applicable to the company pipeline) could materially reduce valuation given the small market cap and binary outcomes.
  • Very limited public disclosure and analyst coverage increases information asymmetry and tail risk from surprise filings or announcements.
  • Market-wide rotations toward large-cap defensive healthcare could further depress small biopharma valuations absent distinct positive news.
  • Low liquidity may make it difficult to exit positions without moving the market and can magnify losses during selling pressure.
  • Macro risk: a broad risk-off shift or tightening financing conditions would disproportionately hurt microcap biotech issuers.

See today's live rating, score and targets

Members see the live hourly rating for ACTU — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.